Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1978 1
1982 1
1986 1
1987 1
1988 2
1990 1
1993 1
1995 1
1996 2
1997 3
1999 2
2000 1
2002 3
2003 2
2004 4
2005 1
2006 1
2007 1
2008 4
2010 3
2011 4
2012 4
2013 3
2014 2
2015 8
2016 10
2017 9
2018 11
2019 10
2020 15
2021 9
2022 15
2023 12
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

125 results

Results by year

Filters applied: . Clear all
Page 1
Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.
Tsurutani J, Iwata H, Krop I, Jänne PA, Doi T, Takahashi S, Park H, Redfern C, Tamura K, Wise-Draper TM, Saito K, Sugihara M, Singh J, Jikoh T, Gallant G, Li BT. Tsurutani J, et al. Cancer Discov. 2020 May;10(5):688-701. doi: 10.1158/2159-8290.CD-19-1014. Epub 2020 Mar 25. Cancer Discov. 2020. PMID: 32213540 Free PMC article. Clinical Trial.
We assessed the safety/tolerability and activity of the novel HER2-targeted antibody-drug conjugate trastuzumab deruxtecan (T-DXd) in 60 patients with pretreated, HER2-expressing (IHC 1+), non-breast/non-gastric or HER2-mutant solid tumors from a phase I trial (NCT02564900 …
We assessed the safety/tolerability and activity of the novel HER2-targeted antibody-drug conjugate trastuzumab deruxtecan (T-DXd) in 60 pat …
Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial.
Vos JL, Burman B, Jain S, Fitzgerald CWR, Sherman EJ, Dunn LA, Fetten JV, Michel LS, Kriplani A, Ng KK, Eng J, Tchekmedyian V, Haque S, Katabi N, Kuo F, Han CY, Nadeem Z, Yang W, Makarov V, Srivastava RM, Ostrovnaya I, Prasad M, Zuur CL, Riaz N, Pfister DG, Klebanoff CA, Chan TA, Ho AL, Morris LGT. Vos JL, et al. Nat Med. 2023 Dec;29(12):3077-3089. doi: 10.1038/s41591-023-02518-x. Epub 2023 Aug 24. Nat Med. 2023. PMID: 37620627 Clinical Trial.
Salivary gland cancers (SGCs) are rare, aggressive cancers without effective treatments when metastasized. We conducted a phase 2 trial evaluating nivolumab (nivo, anti-PD-1) and ipilimumab (ipi, anti-CTLA-4) in 64 patients with metastatic SGC enrolled in two histology-bas …
Salivary gland cancers (SGCs) are rare, aggressive cancers without effective treatments when metastasized. We conducted a phase 2 trial …
Postoperative Management of Salivary Gland Tumors.
Joshi NP, Broughman JR. Joshi NP, et al. Curr Treat Options Oncol. 2021 Feb 9;22(3):23. doi: 10.1007/s11864-021-00820-9. Curr Treat Options Oncol. 2021. PMID: 33560478 Review.
Systemic and Targeted Therapies in Adenoid Cystic Carcinoma.
Kacew AJ, Hanna GJ. Kacew AJ, et al. Curr Treat Options Oncol. 2023 Jan;24(1):45-60. doi: 10.1007/s11864-022-01043-2. Epub 2023 Jan 13. Curr Treat Options Oncol. 2023. PMID: 36637743 Review.
Adenoid cystic carcinoma (ACC) is an often-indolent type of salivary gland cancer (SGC). A subset of patients develops progression or aggressive disease warranting systemic therapy in the recurrent/metastatic (R/M) setting. ...We go on to review other therapi …
Adenoid cystic carcinoma (ACC) is an often-indolent type of salivary gland cancer (SGC). A subset of patients develops …
Management of salivary gland tumors.
Andry G, Hamoir M, Locati LD, Licitra L, Langendijk JA. Andry G, et al. Expert Rev Anticancer Ther. 2012 Sep;12(9):1161-8. doi: 10.1586/era.12.92. Expert Rev Anticancer Ther. 2012. PMID: 23098116 Review.
Adjuvant external radiation is indicated for malignant tumors with high-risk features such as close (or invaded) margins, perineural speed, lymphatic and/or vascular invasion, lymph-node involvement and high-grade histology. A Phase II trial testing adjuvant concomitant ci …
Adjuvant external radiation is indicated for malignant tumors with high-risk features such as close (or invaded) margins, perineural speed, …
Risk of salivary gland cancer after childhood cancer: a report from the Childhood Cancer Survivor Study.
Boukheris H, Stovall M, Gilbert ES, Stratton KL, Smith SA, Weathers R, Hammond S, Mertens AC, Donaldson SS, Armstrong GT, Robison LL, Neglia JP, Inskip PD. Boukheris H, et al. Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):776-83. doi: 10.1016/j.ijrobp.2012.06.006. Epub 2012 Jul 24. Int J Radiat Oncol Biol Phys. 2013. PMID: 22836059 Free PMC article.
PURPOSE: To evaluate effects of radiation therapy, chemotherapy, cigarette smoking, and alcohol consumption on the risk of second primary salivary gland cancer (SGC) in the Childhood Cancer Survivor Study (CCSS). ...
PURPOSE: To evaluate effects of radiation therapy, chemotherapy, cigarette smoking, and alcohol consumption on the risk of second primary …
What is new in the management of salivary gland cancers?
Adelstein DJ, Rodriguez CP. Adelstein DJ, et al. Curr Opin Oncol. 2011 May;23(3):249-53. doi: 10.1097/CCO.0b013e328344f59c. Curr Opin Oncol. 2011. PMID: 21330920 Review.
The recent identification of characteristic molecular signatures in specific histologic subtypes of salivary gland cancer has sparked interest in the potential for better diagnostic classification and more specific, molecularly targeted therapies. ...SUMMARY: …
The recent identification of characteristic molecular signatures in specific histologic subtypes of salivary gland cancer …
125 results